Evidence map›Paper›PMID 31927774›Full record

Trial reportInternational journal of clinical practice2020

Men's Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo-controlled study.

Claus G Roehrborn, Raymond C Rosen, Michael J Manyak, Juan Manuel Palacios-Moreno, Timothy H Wilson, Zrinka Lulic, François Giuliano

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Review
  3. Effects of dutasteride and tamsulosin on penile morphology in a rodent model.International braz j urol : official journal of the Brazilian Society of Urology
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Claus G RoehrbornDepartment of Urology, UT Southwestern Medical Centre, University of Texas, Dallas, TX, USA.
Raymond C RosenHealthCore/New England Research Institutes, Watertown, MA, USA.
Michael J ManyakGSK, Washington, DC, USA.
Juan Manuel Palacios-MorenoGSK, Madrid, Spain.ORCID https://orcid.org/0000-0001-9946-4005
Timothy H WilsonPAREXEL International, Durham, NC, USA.
Zrinka LulicGSK, Brentford, UK.
François GiulianoDepartment of Physical Medicine and Rehabilitation, Raymond Poincaré Hospital, Garches, France.
GlaxoSmithKline (Spain) · ESHôpital Raymond-Poincaré · FRNew England Research Institutes · USPAREXEL International (United States) · USSouthwestern Medical Center · US

Funding

GlaxoSmithKline FDC116115GlaxoSmithKline NCT01777269
6 · The paper itself

Abstract

aimTo assess the impact of baseline characteristics on Men's Sexual Health Questionnaire (MSHQ) total scores and to evaluate the clinical relevance of MSHQ changes and their association with spontaneously reported sexual adverse events (SexAEs) in patients with benign prostatic hyperplasia.

methodsThis was a post hoc analysis of the Phase 4 FDC116115 study, in which patients aged ≥50 years were randomised 1:1 to receive a fixed-dose combination of dutasteride 0.5 mg and tamsulosin 0.4 mg (DUT-TAM FDC), or placebo. End-points included: change in MSHQ total scores by baseline characteristics and SexAEs; cumulative distribution function for change from baseline to month 12 in MSHQ total score and the ejaculation, erection, satisfaction and sexual desire (libido) domain scores; and relationship between changes in MSHQ scores and SexAEs.

resultsThe intent-to-treat population comprised 489 patients (DUT-TAM FDC, n = 243; placebo, n = 246). The mean reduction in total MSHQ score was greater in patients with SexAEs across both groups, compared with patients without SexAEs. Most patients reporting any SexAE (86% DUT-TAM FDC, 67% placebo) had a worsening of the MSHQ total score at month 12 compared with baseline. Specifically, 90% (DUT-TAM FDC) and 75% (placebo) of patients reporting an ejaculation SexAE and 73% (DUT-TAM FDC) and 87% (placebo) of patients reporting an erection SexAE had a worsening of MSHQ ejaculation and erection domain scores, respectively, at month 12. A threshold effect for incident SexAE was observed; patients showing a decrease of approximately 6-10 points in the total MSHQ score were more likely to report SexAEs.

conclusionFindings support the clinical utility of the MSHQ tool in assessing the impact of DUT-TAM on sexual function by linking numerical changes in MSHQ scores to spontaneously reported SexAEs for the first time. The threshold effect for incidence of SexAEs warrants further investigation to determine its clinical relevance.

Indexed as

Sexual HealthAgedDouble-Blind MethodDutasterideEjaculationHumansLibidoLower Urinary Tract SymptomsMaleMen's HealthMiddle AgedPenile ErectionProspective StudiesProstatic HyperplasiaSexual BehaviorSurveys and QuestionnairesDutasterideTamsulosin

Identifiers

PMID31927774
PMCPMC7187250
OpenAlexW2999915370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.